1. Home
  2. Directory
  3. Minnesota
  4. Minneapolis
  5. Physician Assistant
  6. NPI Profile
  7. Prescriptions 1275901316

MS. KATHLEEN RAE SAHLI PA-C
Prescription History 1275901316
Physician Assistant in Minneapolis, MN


Quality Rating: 83.53 out of 100 score

NPI Status: Active since September 07, 2015

Contact Information

800 E 28TH ST STE 401
MINNEAPOLIS, MN
ZIP 55407
Phone: (612) 863-0200
Fax: (612) 863-0235

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. KATHLEEN RAE SAHLI PA-C, an active Physician Assistant specialist practicing in Minneapolis, MN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 62 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 19 claims alone.

Medication Index

A
L
R
T
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 19
30-Day Fills 51.0
Days Supply 1,530
MN State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills143.8
Peer Average Days Supply4,278
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.2% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,018.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.60

State Avg Cost Per Claim

$33.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Letrozole

Generic Formulation: LetrozoleSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 14
30-Day Fills 38.0
Days Supply 1,140
MN State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills119.2
Peer Average Days Supply3,547
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $601.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.94

State Avg Cost Per Claim

$34.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 27.0
Days Supply 810
MN State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills37.4
Peer Average Days Supply1,081
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,646.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$126.67

State Avg Cost Per Claim

$101.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 16
30-Day Fills 46.3
Days Supply 1,390
MN State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills94.4
Peer Average Days Supply2,813
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.9% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $855.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.47

State Avg Cost Per Claim

$41.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. KATHLEEN RAE SAHLI PA-C provides transparency into local medical care patterns within Minneapolis, MN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.